Illumina, Inc. Forecasted to Earn Q3 2025 Earnings of $1.12 Per Share (NASDAQ:ILMN)

Illumina, Inc. (NASDAQ:ILMN) – Research analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for Illumina in a report issued on Tuesday, September 17th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will post earnings of $1.12 per share for the quarter, down from their previous estimate of $1.13. The consensus estimate for Illumina’s current full-year earnings is $3.62 per share. Leerink Partnrs also issued estimates for Illumina’s FY2025 earnings at $4.39 EPS.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the business earned $0.32 earnings per share. The firm’s quarterly revenue was down 5.4% compared to the same quarter last year.

Several other brokerages have also issued reports on ILMN. UBS Group upped their target price on shares of Illumina from $131.00 to $133.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Stephens restated an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, July 10th. Scotiabank cut their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. Royal Bank of Canada restated an “outperform” rating and set a $242.00 price target on shares of Illumina in a research report on Wednesday, August 14th. Finally, Barclays upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 price target for the company in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $151.05.

Illumina Stock Up 0.6 %

Shares of NASDAQ:ILMN opened at $130.97 on Wednesday. Illumina has a 52-week low of $89.00 and a 52-week high of $148.19. The firm has a fifty day moving average of $124.62 and a 200 day moving average of $120.62. The firm has a market capitalization of $20.86 billion, a PE ratio of -16.07 and a beta of 1.15. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11.

Hedge Funds Weigh In On Illumina

Hedge funds have recently bought and sold shares of the company. Trivant Custom Portfolio Group LLC lifted its stake in shares of Illumina by 166.7% in the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after buying an additional 125 shares in the last quarter. Versant Capital Management Inc boosted its stake in Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. bought a new stake in shares of Illumina in the 2nd quarter worth $34,000. Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after purchasing an additional 132 shares during the last quarter. Finally, Principal Securities Inc. bought a new position in shares of Illumina during the fourth quarter valued at $51,000. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.